Published in Rheumatology (Oxford) on May 18, 2004
Women and ischemic heart disease: evolving knowledge. J Am Coll Cardiol (2009) 2.49
Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat Rev Rheumatol (2010) 1.40
Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study. Arthritis Res Ther (2009) 1.29
The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther (2009) 1.15
Myocardial ischemia in women: lessons from the NHLBI WISE study. Clin Cardiol (2012) 1.07
Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. Expert Rev Clin Immunol (2011) 0.96
Risk of coronary artery disease in patients with systemic sclerosis: a systematic review and meta-analysis. Clin Rheumatol (2014) 0.90
Venous thromboembolism in southern Chinese patients with systemic lupus erythematosus. Clin Rheumatol (2010) 0.85
Factors associated with arterial vascular events in PROFILE: a Multiethnic Lupus Cohort. Lupus (2009) 0.85
Age-related differences in the clinical characteristics of systemic lupus erythematosus in children. Rheumatol Int (2012) 0.85
Management of cardiovascular complications in systemic lupus erythematosus. Int J Clin Rheumtol (2010) 0.85
ROCKs as immunomodulators of stroke. Expert Opin Ther Targets (2012) 0.84
Recent advances in the management of chronic stable angina I: approach to the patient, diagnosis, pathophysiology, risk stratification, and gender disparities. Vasc Health Risk Manag (2010) 0.83
Comparative study on circulating endothelial progenitor cells in systemic lupus erythematosus patients at active stage. Rheumatol Int (2009) 0.82
Anti-apolipoprotein A-1 antibodies and carotid intima-media thickness in Egyptian women with systemic lupus erythematosus. Clin Rheumatol (2014) 0.81
Atherosclerotic plaques occur in absence of intima-media thickening in both systemic sclerosis and systemic lupus erythematosus: a duplexsonography study of carotid and femoral arteries and follow-up for cardiovascular events. Arthritis Res Ther (2014) 0.81
Imaging assessment of cardiovascular disease in systemic lupus erythematosus. Clin Dev Immunol (2011) 0.80
Association of systemic lupus erythematosus with angiographically defined coronary artery disease: a retrospective cohort study. Arthritis Care Res (Hoboken) (2013) 0.78
Detection of cerebral embolic signals in patients with systemic lupus erythematosus. J Neurol Neurosurg Psychiatry (2006) 0.78
Inflammatory bowel disease as a risk factor for premature coronary artery disease. J Clin Med Res (2015) 0.78
Von Willebrand factor, red cell fragmentation, and disease activity in systemic lupus erythematosus. HSS J (2008) 0.78
Could antibodies to C-reactive protein link inflammation and cardiovascular disease in patients with systemic lupus erythematosus? Ann Rheum Dis (2007) 0.78
Circulating Angiogenic T Cells and Their Subpopulations in Patients with Systemic Lupus Erythematosus. Mediators Inflamm (2016) 0.77
Nephritis and the risk of acute myocardial infarction in patients with systemic lupus erythematosus. Clin Exp Rheumatol (2010) 0.77
IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study. Arthritis Res Ther (2015) 0.76
Contemporary treatment of systemic lupus erythematosus: an update for clinicians. Ther Adv Chronic Dis (2010) 0.76
Stroke in systemic lupus erythematosus: a meta-analysis of population-based cohort studies. RMD Open (2015) 0.76
Progression of carotid atherosclerosis in patients with systemic lupus erythematosus. Clin Rheumatol (2013) 0.76
Altered lipoproteins in patients with systemic lupus erythematosus are associated with augmented oxidative stress: a potential role in atherosclerosis. Arthritis Res Ther (2016) 0.75
The necessity of stroke prevention in patients with systemic lupus erythematosus. J Res Med Sci (2012) 0.75
Polymyalgia rheumatica and risk of coronary artery disease: a systematic review and meta-analysis of observational studies. Rheumatol Int (2016) 0.75
Risk of ischemic stroke in patients with polymyositis and dermatomyositis: a systematic review and meta-analysis. Rheumatol Int (2014) 0.75
Redox regulation of fos and jun DNA-binding activity in vitro. Science (1990) 7.09
Mortality in systemic lupus erythematosus. Arthritis Rheum (2006) 3.61
The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med (1993) 3.35
Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis Rheum (1999) 2.99
Idiotypic cross-reactions of monoclonal human lupus autoantibodies. J Exp Med (1983) 2.96
Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum (2002) 2.75
Membrane potential and gentamicin uptake in Staphylococcus aureus. Proc Natl Acad Sci U S A (1982) 2.73
Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Br J Rheumatol (1995) 2.69
Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. J Clin Invest (1997) 2.57
Influence of cimetidine on pharmacokinetics of propranolol. Br Med J (Clin Res Ed) (1981) 2.50
The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum (1997) 2.49
BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) (2005) 2.37
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res (2001) 2.35
Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum (2000) 2.28
The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol (2000) 2.26
Associations between drinking water and urinary arsenic levels and skin lesions in Bangladesh. J Occup Environ Med (2000) 2.20
Mixed connective tissue disease--goodbye to all that. Br J Rheumatol (1992) 2.11
Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med (1988) 2.09
Anti-DNA antibody idiotypes in systemic lupus erythematosus. Lancet (1984) 2.08
An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum (2005) 1.96
Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) (2001) 1.96
Fifty years of anti-ds DNA antibodies: are we approaching journey's end? Rheumatology (Oxford) (2007) 1.95
Recrudescence and reinfection with Helicobacter pylori after eradication therapy in Bangladeshi adults. Gastroenterology (2001) 1.88
Prevalence and social correlates of postnatal depression in a low income country. Arch Womens Ment Health (2006) 1.87
Raised serum IgG and IgA antibodies to mycobacterial antigens in rheumatoid arthritis. Ann Rheum Dis (1989) 1.85
Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2010) 1.84
B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) (2005) 1.83
Monoclonal antibodies against hepatitis A virus. J Clin Microbiol (1983) 1.83
Protein kinase C-alpha signals rho-guanine nucleotide dissociation inhibitor phosphorylation and rho activation and regulates the endothelial cell barrier function. J Biol Chem (2001) 1.82
Electrochemical proton gradient in inverted membrane vesicles from Escherichia coli. Biochemistry (1980) 1.78
Binding of cytoskeletal proteins by monoclonal anti-DNA lupus autoantibodies. Clin Immunol Immunopathol (1984) 1.76
Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res (1994) 1.75
Preparation, characterization, and properties of monoclonal antibodies against the lac carrier protein from Escherichia coli. Proc Natl Acad Sci U S A (1982) 1.74
p38 MAP kinase mediates bax translocation in nitric oxide-induced apoptosis in neurons. J Cell Biol (2000) 1.74
Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat Biotechnol (2001) 1.74
Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol (1999) 1.71
Unofficial fees in Bangladesh: price, equity and institutional issues. Health Policy Plan (1999) 1.68
Useful laboratory measurements in the management of systemic lupus erythematosus. Q J Med (1982) 1.68
No association between herpes simplex virus type-2 seropositivity or anogenital lesions and HIV seroconversion among homosexual men. J Acquir Immune Defic Syndr (1990) 1.67
B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum (2006) 1.65
Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int (1995) 1.63
Associates of health status in patients with systemic lupus erythematosus. J Rheumatol (1999) 1.62
B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis (2007) 1.62
Membrane potential in anaerobically growing Staphylococcus aureus and its relationship to gentamicin uptake. Antimicrob Agents Chemother (1983) 1.62
Reconstitution of active transport in proteoliposomes containing cytochrome o oxidase and lac carrier protein purified from Escherichia coli. Proc Natl Acad Sci U S A (1983) 1.60
A review of gastrointestinal manifestations of systemic lupus erythematosus. Rheumatology (Oxford) (1999) 1.60
Treatment adherence and clinical outcome in systemic lupus erythematosus. Rheumatology (Oxford) (2007) 1.59
Detection of cross-reactive anti-DNA antibody idiotypes on renal tissue-bound immunoglobulins from lupus patients. J Clin Invest (1985) 1.59
Measurement of anti-DNA antibodies: a reappraisal using five different methods. Ann Rheum Dis (1987) 1.53
Multiple serologic reactions and their relationship to clinical activity in systemic lupus erythematosus. Arthritis Rheum (1984) 1.53
Problem-based learning as an alternative to lecture-based continuing medical education. J R Soc Med (1998) 1.51
The occurrence, nature and distribution of flares in a cohort of patients with systemic lupus erythematosus: a rheumatological view. Br J Rheumatol (1995) 1.49
Combined coronary artery bypass grafting and abdominal aortic aneurysm repair. Am J Surg (1998) 1.49
Elevated IgG antibody levels to the mycobacterial 65-kDa heat shock protein are characteristic of patients with rheumatoid arthritis. Scand J Immunol (1989) 1.49
The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol (1995) 1.49
Sjögren's syndrome: association with type-1 diabetes mellitus. Br J Rheumatol (1989) 1.48
Prevalence, serological features, response to treatment and outcome of critical peripheral ischaemia in a cohort of lupus patients. Rheumatology (Oxford) (2008) 1.48
Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family. Anesthesiology (1996) 1.48
Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother (1989) 1.48
Detection of cross-reactive anti-DNA antibody idiotypes in the serum of systemic lupus erythematosus patients and of their relatives. Arthritis Rheum (1985) 1.48
Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) (2002) 1.47
Epidemiology of childhood electrocution in Bangladesh: findings of national injury survey. Burns (2010) 1.47
The efficacy of bismuth subsalicylate in the treatment of acute diarrhoea and the prevention of persistent diarrhoea. Acta Paediatr (2001) 1.47
Managing diabetes during glucocorticoid therapy. How to avoid metabolic emergencies. Postgrad Med (1998) 1.46
Galactosylation of IgG associated oligosaccharides: reduction in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity. Lancet (1988) 1.46
Annual review hospital visits for patients with cystic fibrosis. J R Soc Med (2001) 1.46
Epidemiology of childhood burn: yield of largest community based injury survey in Bangladesh. Burns (2008) 1.45
The association of socio-economic status, race, psychosocial factors and outcome in patients with systemic lupus erythematosus. Rheumatology (Oxford) (1999) 1.45
The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages. J Biol Chem (2001) 1.44
Thyroid autoimmunity in systemic lupus erythematosus: the clinical significance of a fluctuating course. Br J Rheumatol (1995) 1.44
Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol (2001) 1.44
Muscle changes in ankylosing spondylitis. Br J Rheumatol (1983) 1.43
Aberrant control of galactosyltransferase in peripheral B lymphocytes and Epstein-Barr virus transformed B lymphoblasts from patients with rheumatoid arthritis. J Rheumatol (1993) 1.43
Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos (1997) 1.43
Purification and molecular genetic characterization of ZPU1, a pullulanase-type starch-debranching enzyme from maize. Plant Physiol (1999) 1.43
Anti-DNA antibodies in the primary antiphospholipid syndrome (PAPS) Br J Rheumatol (1993) 1.42
Lessons learned from a 6-year clinical experience with superior vena cava Greenfield filters. J Vasc Surg (2000) 1.41
Transforming growth factor beta (TGF-beta) and obliterative bronchiolitis following pulmonary transplantation. J Heart Lung Transplant (1999) 1.40
Systemic lupus erythematosus--disease activity, severity, treatment and costs. J Rheumatol (1994) 1.39
Muscle strength and pre-osteomalacia in vegetarian Asian women. Lancet (1982) 1.39
Definition and treatment of lupus flares measured by the BILAG index. Rheumatology (Oxford) (2003) 1.38
A follow-up of vasectomy clients in rural Bangladesh. Int J Gynaecol Obstet (1979) 1.38
Research and training review of the use of LAS, LAT and flexible training positions. Rheumatology (Oxford) (2001) 1.38
The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis (2007) 1.37
Reversal of multidrug resistance in human colon cancer cells expressing the human MDR1 gene by liposomes in combination with monoclonal antibody or verapamil. J Natl Cancer Inst (1995) 1.37
Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) (2002) 1.37
Mycobacteria and autoimmunity. Immunol Today (1988) 1.36
An immunohistological study of secondary Sjögren's syndrome. Ann Rheum Dis (1984) 1.36
Effect of diethylpyrocarbonate on lactose/proton symport in Escherichia coli membrane vesicles. Proc Natl Acad Sci U S A (1979) 1.34
Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis (2001) 1.34
Characterization of polymyositis infiltrates using monoclonal antibodies to human leucocyte antigens. Clin Exp Immunol (1981) 1.33
Foreign bodies in the maxillary antrum. Br Dent J (1982) 1.31
SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol (1996) 1.30
Cytochrome o type oxidase from Escherichia coli. Characterization of the enzyme and mechanism of electrochemical proton gradient generation. Biochemistry (1984) 1.30
Functional disability and end organ damage in patients with systemic lupus erythematosus (SLE), SLE and Sjögren's syndrome (SS), and primary SS. J Rheumatol (1998) 1.30
Recruitment of the nuclear receptor corepressor N-CoR by the TEL moiety of the childhood leukemia-associated TEL-AML1 oncoprotein. Blood (2000) 1.29
Nutritional rickets without vitamin D deficiency in Bangladesh. J Trop Pediatr (1999) 1.29